Perospiron
Idi na navigaciju
Idi na pretragu
![]() | |||
(IUPAC) ime | |||
---|---|---|---|
(3aR,7aS)-24-[4-(1,2-benzizotiazol-3-il)piperazin-1-il]butil}heksahidro-1H-izoindol-1,3(2H)-dion | |||
Klinički podaci | |||
Robne marke | Lulan | ||
AHFS/Drugs.com | Internacionalno ime leka | ||
Identifikatori | |||
CAS broj | 150915-41-6 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 115368 | ||
ChemSpider[3] | 16737064 | ||
UNII | N303OK87DT ![]() | ||
Hemijski podaci | |||
Formula | C23H30N4O2S | ||
Mol. masa | 426,57 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakokinetički podaci | |||
Poluvreme eliminacije | 2-2,5 sata | ||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | ℞ Prescription only | ||
Način primene | Oralnot |
Perospiron (Lulan) je atipični antipsihotik iz azapironske hemijske klase.[4] Njega je razvila japanska kompanija Dajnipon sumitomo farma 2001 za lečenje šizofrenije i akutne bipolarne manije.[5][6] Perospiron deluje kao parcijalni agonist 5-HT1A receptora, inverzni agonist 5-HT2A receptora i antagonist D2, D4 i α1-adrenergičkog receptora.[7][8][9][10]
Reference[uredi - уреди | uredi izvor]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. http://www.sciencedirect.com/science/article/pii/S1359644610007737.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. http://www.jcheminf.com/content/2/1/3.
- ↑ Onrust SV, McClellan K (2001). "Perospirone". CNS Drugs 15 (4): 329–37; discussion 338. DOI:10.2165/00023210-200115040-00006. PMID 11463136.
- ↑ de Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)". Current Opinion in Investigational Drugs (London, England : 2000) 3 (1): 121–9. PMID 12054062.
- ↑ "Sumitomo Pharmaceuticals 2001 | News Release | Dainippon Sumitomo Pharma". http://www.ds-pharma.co.jp/english/news/sumitomo_2001/no_002.html.
- ↑ Hirose A, Kato T, Ohno Y, et al. (July 1990). "Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions". Japanese Journal of Pharmacology 53 (3): 321–9. DOI:10.1254/jjp.53.321. PMID 1975278. http://www.ncbi.nlm.nih.gov/pubmed/1975278.
- ↑ Kato T, Hirose A, Ohno Y, Shimizu H, Tanaka H, Nakamura M (December 1990). "Binding profile of SM-9018, a novel antipsychotic candidate". Japanese Journal of Pharmacology 54 (4): 478–81. DOI:10.1254/jjp.54.478. PMID 1982326. http://www.ncbi.nlm.nih.gov/pubmed/1982326.
- ↑ Odagaki Y, Toyoshima R (2007). "5-HT1A receptor agonist properties of antipsychotics determined by [35SGTPgammaS binding in rat hippocampal membranes"]. Clinical and Experimental Pharmacology & Physiology 34 (5–6): 462–6. DOI:10.1111/j.1440-1681.2007.04595.x. PMID 17439416. http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0305-1870&date=2007&volume=34&issue=5-6&spage=462.
- ↑ Seeman P, Tallerico T (March 1998). "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors". Molecular Psychiatry 3 (2): 123–34. DOI:10.1038/sj.mp.4000336. PMID 9577836.
Vidi još[uredi - уреди | uredi izvor]
Spoljašnje veze[uredi - уреди | uredi izvor]
|
|
|
![]() |
Molimo Vas, obratite pažnju na važno upozorenje u vezi tema o zdravlju (medicini). |